All therapiesEvidence snapshot 2026-09-13
Weight & glucose

Berobenatide

A long-acting peptide that activates GLP-1 receptors; weekly and monthly dosing are being studied.

GLP-1s & metabolic therapies

At a glance

Selected evidence in this atlas
Studied use & population

Adults with obesity or overweight and hypertension/dyslipidemia, without diabetes

Study context
Approval & development

Investigational; phase 3 VESPER program ongoing

Status & indications
Selected efficacy evidence

12.1% reported weight loss · 0.2% gain with placebo · 28 weeks

VESPER-3 · Phase 2b · sponsor · 4.8 mg every 4 weeks after 0.4, 0.8 and 1.2 mg weekly, each for 4 weeks · Assuming continued treatment

Evidence & limitations
Important safety context

9.3% discontinued for adverse events in selected arm; nausea 40.7%, vomiting 22.2%.

Safety context
Next milestone

A next milestone is not summarized for this therapy.

Milestone details

Study results apply to their own population, dose and analysis. They do not establish a ranking between therapies.

Evidence in the atlas

3 results

Each result belongs to its own study population, dose and analysis. Open a result for its chart, comparator, safety findings and limitations.

Weight loss

VESPER-3

12.1% reported weight loss · 0.2% gain with placebo · 28 weeks

4.8 mg every 4 weeks after 0.4, 0.8 and 1.2 mg weekly, each for 4 weeks

Adults with obesity or overweight and hypertension/dyslipidemia, without diabetes

Trial-product on-treatment MMRM excludes post-discontinuation, non-compliance and lifestyle-change data. Absolute endpoint labels verified visually on slide 69. Investigational; phase 3 VESPER program ongoing

Safety context

9.3% discontinued for adverse events in selected arm; nausea 40.7%, vomiting 22.2%.

Limitations: Placebo gained 0.2%, encoded as negative loss. Trial continued beyond this prespecified interim endpoint.

Explore result Compare study Pfizer Pflash ADA 2026: VESPER-3 weight change at week 28 · 2026-06-06
Weight loss

VESPER-1 randomized double-blind Part A

12.5% reported weight loss · 1.7% gain with placebo · 28 weeks

1.2 mg once weekly

Adults with obesity or overweight and hypertension/dyslipidemia, without diabetes

Adherence-to-study MMRM excludes data after permanent discontinuation, non-compliance, or lifestyle change. Absolute values labeled in sponsor Figure, slide 34. Investigational; phase 3 VESPER program ongoing

Safety context

GI adverse events reported; sponsor presents dose-specific tolerability separately.

Limitations: Placebo gained 1.7%, encoded as negative loss. Open-label extension and modeled 72-week predictions excluded.

Explore result Compare study Pfizer Pflash ADA 2026: VESPER-1 weight change at week 28 · 2026-06-06
Glucose control

VESPER-2

2.2 percentage-point HbA1c decrease · 0.2 pp decrease with Placebo · 28 weeks

1.6 mg weekly after escalation

Adults with overweight/obesity and type 2 diabetes

Trial-product estimand; repeated-measures model excluding data after discontinuation, non-compliance, or lifestyle change. No imputation of missing values.

Safety context

At 1.6 mg: any adverse event 70.4%, serious events 7.4%, discontinuation for adverse events 7.4%; placebo 57.7%, 3.8%, and 0%. Neither serious event in this dose arm was considered drug-related.

Limitations: 133 randomized, 132 treated. HbA1c was secondary; the placebo-subtracted decrease was 2.0 pp.

Explore result Compare study VESPER-2, ADA presentation slides 48–56 · 2026-06-06

Biology & identity

Status in this atlas: Investigational; phase 3 VESPER program ongoing

Hormone activity

GLP-1Activates receptors

A long-acting peptide that activates GLP-1 receptors; weekly and monthly dosing are being studied.

What do these hormones do? GLP-1

Investigational; no approved trade name identified as of 2026-09-13. Berobenatide, PF-08653944/PF’3944 and MET-097i are compound names or codes. Weekly and monthly regimens are not separate brands.

Pfizer · Current owner/developer following its completed Metsera acquisition.; Metsera · Prior development company for MET-097i; acquired as a Pfizer subsidiary.

Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.

The molecule

A long-acting peptide that activates GLP-1 receptors; weekly and monthly dosing are being studied.
Structure not yet verified

Structure not verified

A long-acting peptide that activates GLP-1 receptors; weekly and monthly dosing are being studied.

Shown: Peptide drug

An exact-drug structure was not verified in this review. The named PubChem lookup did not return a compound record; no related hormone or analogue is substituted.

Berobenatide

Development timeline

Next milestone

A next milestone is not summarized for this therapy. This does not mean development has ended.

Development history2 selected milestones

Berobenatide · compound history across indications

Selected milestones only. Earlier studies may be missing; the first listed date should not be interpreted as the start of development.

  1. Pfizer acquired Metsera

    Pfizer completed its acquisition of Metsera and its obesity portfolio.

    Source

  2. Weekly and monthly phase 2b results

    Pfizer presented VESPER-1, VESPER-2 and VESPER-3 data and reported its phase 3 VESPER program underway.

    Source

Selected sources checked Sep 13, 2026. This is not an exhaustive history.